 Aurinia Pharmaceuticals Inc NASDAQ: AUPH has announced that The Lancet published its Phase 3 AURORA 1 study evaluating Lupkynis voclosporin in adults with lupus nephritis LN. The study results demonstrated that Lupkynis combined with mycophenolate mofetil MMF and low-dose corticosteroids led to statistically superior complete renal response rates at 52 weeks compared to treatment with MMF and low-dose corticosteroids alone, with a comparable safety profile. 